Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM06S9X)

• Drug Name: [125I]SCH23982 Drug Info
• Synonyms: [125I]-SCH23982

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 119353
  CAS Number: CAS 116780-39-3
  TTD Drug ID: DM06S9X

Molecule-Related Drug Atlas

Drug(s) Targeting Dopamine D1 receptor (D1R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Phenyltoloxamine	DMKAEQW	Allergy	4A80-4A85	Approved	[4]
Pergolide	DM14MAE	Parkinson disease	8A00.0	Approved	[5]
Methylergonovine	DMBEX4O	Spontaneous abortion	JA00.0	Approved	[6]
Fenoldopam	DMFAOKP	Hypertension	BA00-BA04	Approved	[7]
Zicronapine	DMP8ESD	Schizophrenia	6A20	Phase 3	[8]
Ecopipam	DMS9R43	Cocaine addiction	6C45.2	Phase 3	[9]
DAS-431	DMM3BPL	Dementia	6D80-6D86	Phase 2	[10]
Dihydrexidine	DMACPQO	Psychotic disorder	6A20-6A25	Phase 1/2	[11]
BAM-1110	DMPMKUF	Parkinson disease	8A00.0	Discontinued in Phase 2	[12]
CY-208243	DMP8TKA	Pain	MG30-MG3Z	Discontinued in Phase 2	[13]

Drug(s) Targeting Dopamine D5 receptor (D5R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Phenyltoloxamine	DMKAEQW	Allergy	4A80-4A85	Approved	[4]
LE-300	DMGJL16	Schizophrenia	6A20	Preclinical	[14]
ZD-3638	DM6M9GC	Schizophrenia	6A20	Terminated	[14]
GMC-283	DMT1RH6	Schizophrenia	6A20	Terminated	[14]
(+/-)-nantenine	DM0L3GE	Discovery agent	N.A.	Investigative	[15]
ISOCLOZAPINE	DM52CPU	Discovery agent	N.A.	Investigative	[16]
FLUMEZAPINE	DMW0HOG	Discovery agent	N.A.	Investigative	[17]
ISOLOXAPINE	DMH1BN4	Discovery agent	N.A.	Investigative	[18]
1-Dibenzo[b,f]oxepin-10-yl-4-methyl-piperazine	DMOL2Y0	Discovery agent	N.A.	Investigative	[16]
1-[3-(2-Benzyl-phenoxy)-propyl]-pyrrolidine	DMD2NXL	Discovery agent	N.A.	Investigative	[4]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Dopamine D1 receptor (D1R)	TTZFYLI	DRD1_HUMAN	Antagonist	[2]
Dopamine D5 receptor (D5R)	TTS2PH3	DRD5_HUMAN	Antagonist	[3]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 945).
• [2] Molecular cloning and expression of the gene for a human D1 dopamine receptor. Nature. 1990 Sep 6;347(6288):72-6.
• [3] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 218).
• [4] Dopamine/serotonin receptor ligands. 9. Oxygen-containing midsized heterocyclic ring systems and nonrigidized analogues. A step toward dopamine D5 ... J Med Chem. 2004 Aug 12;47(17):4155-8.
• [5] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [6] Reinforcement in an in vitro analog of appetitive classical conditioning of feeding behavior in Aplysia: blockade by a dopamine antagonist. Learn Mem. 2005 May-Jun;12(3):216-20.
• [7] Etiology of iodinated radiocontrast nephrotoxicity and its attenuation by beraprost. Yakugaku Zasshi. 2008 Jul;128(7):1023-9.
• [8] Clinical pipeline report, company report or official report of Lundbeck.
• [9] A D1 receptor antagonist, ecopipam, for treatment of tics in Tourette syndrome.Clin Neuropharmacol.2014 Jan-Feb;37(1):26-30.
• [10] Adrogolide HCl (ABT-431; DAS-431), a prodrug of the dopamine D1 receptor agonist, A-86929: preclinical pharmacology and clinical data. CNS Drug Rev. 2001 Fall;7(3):305-16.
• [11] trans-2,3-dihydroxy-6a,7,8,12b-tetrahydro-6H-chromeno[3,4-c]isoquinoline: synthesis, resolution, and preliminary pharmacological characterization o... J Med Chem. 2006 Nov 16;49(23):6848-57.
• [12] Therapeutic effects of dopamine D1/D2 receptor agonists on detrusor hyperreflexia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned parkinso... J Pharmacol Exp Ther. 1998 Jul;286(1):228-33.
• [13] The D-1 dopamine receptor partial agonist, CY 208-243, exhibits antiparkinsonian activity in the MPTP-treated marmoset. Eur J Pharmacol. 1988 Nov 1;156(2):197-206.
• [14] The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
• [15] Synthetic studies and pharmacological evaluations on the MDMA ('Ecstasy') antagonist nantenine. Bioorg Med Chem Lett. 2010 Jan 15;20(2):628-31.
• [16] Affinity of 10-(4-methylpiperazino)dibenz[b,f]oxepins for clozapine and spiroperidol binding sites in rat brain. J Med Chem. 1982 Jul;25(7):855-8.
• [17] Effects of conformationally restricted 4-piperazinyl-10H-thienobenzodiazepine neuroleptics on central dopaminergic and cholinergic systems. J Med Chem. 1982 Oct;25(10):1133-40.
• [18] Synthesis of clozapine analogues and their affinity for clozapine and spiroperidol binding sites in rat brain. J Med Chem. 1981 Sep;24(9):1021-6.